An interventional study of lipodia in Hypercholesterolemia and Dyslipidemias, sponsored by Gaia AG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Gaia AG · Not applicable, Interventional, and Treatment
Among 81 studies in Hypercholesterolemia with a site in Germany — 6 open to participants now, 11 under way, 7 of them phase 3. Hypercholesterolemia · Germany.
Among the 81 studies in Hypercholesterolemia with a site in Germany, this one is the 39th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 71st registered.
1,175 studies on the registry are indexed under Hypercholesterolemia; 93 are open to participants now.
This study's enrollment of 278 is above the median of 110 across 975 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →6 of the 81 studies in Hypercholesterolemia with a site in Germany are open now, in 12 countries. Each count lists the studies.
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →81 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2025.
Median enrollment 306 across the 74 interventional studies, 1,868 across the 7 observational. Of the 69 that completed or were terminated, 34 (49%) have results posted.
62 of 81 have an industry lead sponsor. The 10 most frequent:
Gaia AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Gaia AG has 1 study filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypercholesterolemia with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07619118Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia | 2027-05-28 |
| NCT07619131Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | 2027-07-30 |
| NCT07406191University of Erlangen-Nürnberg Medical SchoolWB-EMS Effects on Cardiometabolic Risk Factors | 2027-11-30 |
Among the 81 studies in Hypercholesterolemia with a site in Germany, from their registry updates:
The goal of this clinical trial is to find out if lipodia, a digital health intervention, can help lower cholesterol levels and improve other health measures in adults with high cholesterol.
The main questions it aims to answer are:
Researchers will compare two groups:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Participants allocated to the intervention group will receive access to lipodia in addition to treatment as usual (TAU). lipodia is a digital health application designed for individuals with hypercholesterinemia, accessible through a web browser. The application focuses on treatment methods derived health behavior change and cognitive behavioral therapy (CBT). Topics addressed by lipodia are activity planning and impulse control, dietary habits, physical activity, stress management, mood management, sleep management, weight management, as well as quitting smoking and drinking. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 365 days.
Behavioral: lipodia
Participants allocated to the control group will receive access to treatment as usual (TAU).
Participants will receive access to the digital health intervention lipodia in addition to TAU.
Fasting LDL-C levels
Time frame: 6 months
Patients' activation
Assessed with the total score of the PAM-13. Higher scores indicate higher patient activation (better outcome).
Time frame: 6 months
Fasting non-HDL-C levels
Time frame: 6 months
Health-related quality of life
Assessed with the total score of the AQoL-8D. Higher scores indicate higher quality of life (better outcome).
Time frame: 6 months
BMI
Time frame: 6 months
Fasting triglyceride levels
Time frame: 6 months
Fasting HDL-C levels
Time frame: 6 months
Fasting LDL-C levels
Time frame: 3 months
Patients' activation
Assessed with the total score of the PAM-13. Higher scores indicate higher patient activation (better outcome).
Time frame: 3 months
Fasting non-HDL-C levels
Time frame: 3 months
Health-related quality of life
Assessed with the total score of the AQoL-8D. Higher scores indicate higher quality of life (better outcome).
Time frame: 3 months
BMI
Time frame: 3 months
Fasting triglyceride levels
Time frame: 3 months
Fasting HDL-C levels
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in May 2026, 15 months.
Of 151 interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's 15 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gaia AG